Integrative genomic and transcriptomic analysis of leiomyosarcoma

Priya Chudasama, Sadaf S. Mughal, Mathijs A. Sanders, Daniel Hübschmann, Inn Chung, Katharina I. Deeg, Siao-Han Wong, Sophie Rabe, Mario Hlevnjak, Marc Zapatka, Aurélie Ernst, Kortine Kleinheinz, Matthias Schlesner, Lina Sieverling, Barbara Klink, Evelin Schröck, Remco M. Hoogenboezem, Bernd Kasper, Christoph E. Heilig, Gerlinde Egerer, Stephan Wolf, Christof von Kalle, Roland Eils, Albrecht Stenzinger, Wilko Weichert, Hanno Glimm, Stefan Gröschel, Hans‐Georg Kopp, Georg W. Omlor, Burkhard Lehner, Sebastian Bauer, Simon Schimmack, Alexis Ulrich, Gunhild Mechtersheimer, Karsten Rippe, Benedikt Brors, Barbara Hutter, Marcus Renner, Peter Hohenberger, Claudia Scholl, Stefan FröhlingNature Communications 2018 · DOI

Abstract

Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic options. The mechanisms underlying LMS development, including clinically actionable genetic vulnerabilities, are largely unknown. Here we show, using whole-exome and transcriptome sequencing, that LMS tumors are characterized by substantial mutational heterogeneity, near-universal inactivation of TP53 and RB1, widespread DNA copy number alterations including chromothripsis, and frequent whole-genome duplication. Furthermore, we detect alternative telomere lengthening in 78% of cases and identify recurrent alterations in telomere maintenance genes such as ATRX, RBL2, and SP100, providing insight into the genetic basis of this mechanism. Finally, most tumors display hallmarks of "BRCAness", including alterations in homologous recombination DNA repair genes, multiple structural rearrangements, and enrichment of specific mutational signatures, and cultured LMS cells are sensitive towards olaparib and cisplatin. This comprehensive study of LMS genomics has uncovered key biological features that may inform future experimental research and enable the design of novel therapies.

Introduction

Leiomyosarcoma (LMS) is an aggressive cancer of smooth muscle origin with a dismal prognosis once it metastasizes, with median survival rates of roughly 12 months. Historically, LMS has been a "black box" for precision medicine due to a lack of clear, single-driver mutations. While older cytogenetic studies described LMS as having "chaotic" genomes, high-resolution mapping of specific genetic vulnerabilities was needed to move beyond simple descriptions of chromosomal messiness to find actionable biological patterns.

Methods

The researchers performed an integrative analysis on a cohort of 49 adult LMS patients (39 non-uterine, 10 uterine) using:

  • Whole-Exome Sequencing (WES): To identify somatic mutations (SNVs and indels) and copy-number alterations (CNAs).
  • Transcriptome Sequencing (RNA-seq): To analyze gene expression profiles and identify high-confidence fusion transcripts.
  • C-circle Assays: A specialized biochemical test to detect Alternative Lengthening of Telomeres (ALT).
  • Bioinformatics Pipelines: Tools like MutSigCV for identifying driver genes and HotNet2 for gene network analysis.
  • Functional Validation: Testing the "BRCAness" hypothesis using clonogenic assays on LMS cell lines treated with the PARP inhibitor olaparib and cisplatin.

Key Results and Insights

The Genomic Landscape of LMS

The study revealed that while LMS has a moderate mutation rate, it is defined by extreme structural complexity. A unifying feature discovered is the near-universal biallelic inactivation of TP53 and RB1. Integrating mutations, deletions, and fusions, over 90% of cases showed inactivation of both genes, suggesting this loss is the foundational event in LMS development.

Oncoprint showing the landscape of somatic alterations across 49 LMS samples, highlighting the high frequency of TP53, RB1, and ATRX mutations.

Network analysis further underscored the central role of these tumor suppressors, identifying them as major hubs in the LMS mutational landscape, often interacting with other recurrently altered genes like PTEN.

Gene interaction network highlighting TP53 and RB1 as central hubs in leiomyosarcoma.

ALT Dominance and Genomic Instability

The genomic "chaos" in LMS is often the result of chromothripsis and whole-genome duplication (WGD), the latter occurring in 55% of cases. Notably, 78% of LMS tumors use Alternative Lengthening of Telomeres (ALT) to achieve immortality—the highest frequency reported for any tumor type. The study identified RBL2 and SP100 as novel candidate drivers of this process.

The "BRCAness" Signature and Therapeutic Potential

Most LMS tumors display a "BRCAness" genomic signature, characterized by specific mutational scars and structural rearrangements typical of homologous recombination repair (HRR) deficiency. In vitro testing showed that LMS cell lines were highly sensitive to the PARP inhibitor olaparib, with enhanced effects when combined with cisplatin. This provides a strong preclinical rationale for repositioning these drugs for LMS patients.

Limitations and Future Work

While comprehensive, the study's cohort size (49 patients) means larger studies are needed to further distinguish uterine and non-uterine LMS biology. Additionally, the authors emphasize that genomics-guided clinical trials are the necessary next step to determine if the observed "BRCAness" phenotype translates to real-world patient responses.

Summary updated

Abstract

Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic options. The mechanisms underlying LMS development, including clinically actionable genetic vulnerabilities, are largely unknown. Here we show, using whole-exome and transcriptome sequencing, that LMS tumors are characterized by substantial mutational heterogeneity, near-universal inactivation of TP53 and RB1, widespread DNA copy number alterations including chromothripsis, and frequent whole-genome duplication. Furthermore, we detect alternative telomere lengthening in 78% of cases and identify recurrent alterations in telomere maintenance genes such as ATRX, RBL2, and SP100, providing insight into the genetic basis of this mechanism. Finally, most tumors display hallmarks of "BRCAness", including alterations in homologous recombination DNA repair genes, multiple structural rearrangements, and enrichment of specific mutational signatures, and cultured LMS cells are sensitive towards olaparib and cisplatin. This comprehensive study of LMS genomics has uncovered key biological features that may inform future experimental research and enable the design of novel therapies.
BibTeX
@inproceedings{chudasama2018integrative,
  author = {Priya Chudasama and Sadaf S. Mughal and Mathijs A. Sanders and Daniel Hübschmann and Inn Chung and Katharina I. Deeg and Siao-Han Wong and Sophie Rabe and Mario Hlevnjak and Marc Zapatka and Aurélie Ernst and Kortine Kleinheinz and Matthias Schlesner and Lina Sieverling and Barbara Klink and Evelin Schröck and Remco M. Hoogenboezem and Bernd Kasper and Christoph E. Heilig and Gerlinde Egerer and Stephan Wolf and Christof von Kalle and Roland Eils and Albrecht Stenzinger and Wilko Weichert and Hanno Glimm and Stefan Gröschel and Hans‐Georg Kopp and Georg W. Omlor and Burkhard Lehner and Sebastian Bauer and Simon Schimmack and Alexis Ulrich and Gunhild Mechtersheimer and Karsten Rippe and Benedikt Brors and Barbara Hutter and Marcus Renner and Peter Hohenberger and Claudia Scholl and Stefan Fröhling},
  title = {{Integrative genomic and transcriptomic analysis of leiomyosarcoma}},
  booktitle = {Nature Communications},
  year = {2018},
  doi = {10.1038/s41467-017-02602-0},
}
Figure